Cargando…
Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model
Enterohemorrhagic Escherichia coli (EHEC) is the most common cause of hemorrhagic colitis and hemolytic uremic syndrome in human patients, with brain damage and dysfunction the main cause of acute death. We evaluated the efficacy of urtoxazumab (TMA-15, Teijin Pharma Limited), a humanized monoclonal...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331429/ https://www.ncbi.nlm.nih.gov/pubmed/28134751 http://dx.doi.org/10.3390/toxins9020049 |
_version_ | 1782511374827520000 |
---|---|
author | Moxley, Rodney A. Francis, David H. Tamura, Mizuho Marx, David B. Santiago-Mateo, Kristina Zhao, Mojun |
author_facet | Moxley, Rodney A. Francis, David H. Tamura, Mizuho Marx, David B. Santiago-Mateo, Kristina Zhao, Mojun |
author_sort | Moxley, Rodney A. |
collection | PubMed |
description | Enterohemorrhagic Escherichia coli (EHEC) is the most common cause of hemorrhagic colitis and hemolytic uremic syndrome in human patients, with brain damage and dysfunction the main cause of acute death. We evaluated the efficacy of urtoxazumab (TMA-15, Teijin Pharma Limited), a humanized monoclonal antibody against Shiga toxin (Stx) 2 for the prevention of brain damage, dysfunction, and death in a piglet EHEC infection model. Forty-five neonatal gnotobiotic piglets were inoculated orally with 3 × 10(9) colony-forming units of EHEC O157:H7 strain EDL933 (Stx1(+), Stx2(+)) when 22–24 h old. At 24 h post-inoculation, piglets were intraperitoneally administered placebo or TMA-15 (0.3, 1.0 or 3.0 mg/kg body weight). Compared to placebo (n = 10), TMA-15 (n = 35) yielded a significantly greater probability of survival, length of survival, and weight gain (p <0.05). The efficacy of TMA-15 against brain lesions and death was 62.9% (p = 0.0004) and 71.4% (p = 0.0004), respectively. These results suggest that TMA-15 may potentially prevent or reduce vascular necrosis and infarction of the brain attributable to Stx2 in human patients acutely infected with EHEC. However, we do not infer that TMA-15 treatment will completely protect human patients infected with EHEC O157:H7 strains that produce both Stx1 and Stx2. |
format | Online Article Text |
id | pubmed-5331429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53314292017-03-13 Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model Moxley, Rodney A. Francis, David H. Tamura, Mizuho Marx, David B. Santiago-Mateo, Kristina Zhao, Mojun Toxins (Basel) Article Enterohemorrhagic Escherichia coli (EHEC) is the most common cause of hemorrhagic colitis and hemolytic uremic syndrome in human patients, with brain damage and dysfunction the main cause of acute death. We evaluated the efficacy of urtoxazumab (TMA-15, Teijin Pharma Limited), a humanized monoclonal antibody against Shiga toxin (Stx) 2 for the prevention of brain damage, dysfunction, and death in a piglet EHEC infection model. Forty-five neonatal gnotobiotic piglets were inoculated orally with 3 × 10(9) colony-forming units of EHEC O157:H7 strain EDL933 (Stx1(+), Stx2(+)) when 22–24 h old. At 24 h post-inoculation, piglets were intraperitoneally administered placebo or TMA-15 (0.3, 1.0 or 3.0 mg/kg body weight). Compared to placebo (n = 10), TMA-15 (n = 35) yielded a significantly greater probability of survival, length of survival, and weight gain (p <0.05). The efficacy of TMA-15 against brain lesions and death was 62.9% (p = 0.0004) and 71.4% (p = 0.0004), respectively. These results suggest that TMA-15 may potentially prevent or reduce vascular necrosis and infarction of the brain attributable to Stx2 in human patients acutely infected with EHEC. However, we do not infer that TMA-15 treatment will completely protect human patients infected with EHEC O157:H7 strains that produce both Stx1 and Stx2. MDPI 2017-01-26 /pmc/articles/PMC5331429/ /pubmed/28134751 http://dx.doi.org/10.3390/toxins9020049 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Moxley, Rodney A. Francis, David H. Tamura, Mizuho Marx, David B. Santiago-Mateo, Kristina Zhao, Mojun Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model |
title | Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model |
title_full | Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model |
title_fullStr | Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model |
title_full_unstemmed | Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model |
title_short | Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model |
title_sort | efficacy of urtoxazumab (tma-15 humanized monoclonal antibody specific for shiga toxin 2) against post-diarrheal neurological sequelae caused by escherichia coli o157:h7 infection in the neonatal gnotobiotic piglet model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331429/ https://www.ncbi.nlm.nih.gov/pubmed/28134751 http://dx.doi.org/10.3390/toxins9020049 |
work_keys_str_mv | AT moxleyrodneya efficacyofurtoxazumabtma15humanizedmonoclonalantibodyspecificforshigatoxin2againstpostdiarrhealneurologicalsequelaecausedbyescherichiacolio157h7infectionintheneonatalgnotobioticpigletmodel AT francisdavidh efficacyofurtoxazumabtma15humanizedmonoclonalantibodyspecificforshigatoxin2againstpostdiarrhealneurologicalsequelaecausedbyescherichiacolio157h7infectionintheneonatalgnotobioticpigletmodel AT tamuramizuho efficacyofurtoxazumabtma15humanizedmonoclonalantibodyspecificforshigatoxin2againstpostdiarrhealneurologicalsequelaecausedbyescherichiacolio157h7infectionintheneonatalgnotobioticpigletmodel AT marxdavidb efficacyofurtoxazumabtma15humanizedmonoclonalantibodyspecificforshigatoxin2againstpostdiarrhealneurologicalsequelaecausedbyescherichiacolio157h7infectionintheneonatalgnotobioticpigletmodel AT santiagomateokristina efficacyofurtoxazumabtma15humanizedmonoclonalantibodyspecificforshigatoxin2againstpostdiarrhealneurologicalsequelaecausedbyescherichiacolio157h7infectionintheneonatalgnotobioticpigletmodel AT zhaomojun efficacyofurtoxazumabtma15humanizedmonoclonalantibodyspecificforshigatoxin2againstpostdiarrhealneurologicalsequelaecausedbyescherichiacolio157h7infectionintheneonatalgnotobioticpigletmodel |